FDA Head Seeks IG Probe Of Biogen Alzheimer's Drug Talks

Law360 (July 9, 2021, 6:59 PM EDT) -- The acting head of the Food and Drug Administration said Friday that she had asked for an investigation into conversations between members of her agency and Biogen representatives prior to the FDA's approval of the company's Alzheimer's treatment aducanumab.

Following Thursday's announcement that the FDA would rein in the recommended patient population for aducanumab, also known by the brand name Aduhelm, acting Commissioner Janet Woodcock sent a letter to the U.S. Department of Health and Human Services' Office of Inspector General seeking an independent review and assessment of all interactions between the Biogen reps and her office.

She asked the watchdog...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!